W D Figg

457 total citations
6 papers, 357 citations indexed

About

W D Figg is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, W D Figg has authored 6 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in W D Figg's work include Prostate Cancer Treatment and Research (2 papers), Hormonal and reproductive studies (1 paper) and Radiopharmaceutical Chemistry and Applications (1 paper). W D Figg is often cited by papers focused on Prostate Cancer Treatment and Research (2 papers), Hormonal and reproductive studies (1 paper) and Radiopharmaceutical Chemistry and Applications (1 paper). W D Figg collaborates with scholars based in United States, Ukraine and Italy. W D Figg's co-authors include A Tompkins, E Reed, David Köhler, Paul H. Duray, W. M. Linehan, Elizabeth C. Jones, S. M. Steinberg, William Dahut, Erwin A. Kruger and James M. Pluda and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Neuro-Oncology and Prostate Cancer and Prostatic Diseases.

In The Last Decade

W D Figg

6 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
W D Figg United States	5	222	147	99	96	82	6	357
Albaha Barqawi United States	5	187 0.8×	107 0.7×	167 1.7×	70 0.7×	36 0.4×	10	351
P. Dieringer United States	7	158 0.7×	299 2.0×	203 2.1×	76 0.8×	150 1.8×	10	501
John Bernard France	5	363 1.6×	87 0.6×	135 1.4×	135 1.4×	90 1.1×	8	472
Susan K. Roethke United States	5	234 1.1×	121 0.8×	127 1.3×	92 1.0×	36 0.4×	6	339
L. Hart United States	11	183 0.8×	220 1.5×	254 2.6×	66 0.7×	23 0.3×	25	518
Selena Dixon United Kingdom	2	159 0.7×	105 0.7×	70 0.7×	77 0.8×	81 1.0×	7	248
Davide Bosso Italy	12	167 0.8×	133 0.9×	132 1.3×	70 0.7×	34 0.4×	18	366
Sumiko Okubo Japan	10	68 0.3×	116 0.8×	165 1.7×	40 0.4×	27 0.3×	25	296
N. Agarwal United States	6	295 1.3×	151 1.0×	122 1.2×	126 1.3×	22 0.3×	14	348
H Goulding United Kingdom	5	83 0.4×	185 1.3×	194 2.0×	133 1.4×	23 0.3×	7	429

Countries citing papers authored by W D Figg

Since Specialization

Citations

This map shows the geographic impact of W D Figg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W D Figg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W D Figg more than expected).

Fields of papers citing papers by W D Figg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W D Figg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W D Figg. The network helps show where W D Figg may publish in the future.

Co-authorship network of co-authors of W D Figg

This figure shows the co-authorship network connecting the top 25 collaborators of W D Figg. A scholar is included among the top collaborators of W D Figg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W D Figg. W D Figg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Warren, Katherine E., et al.. (2019). DIPG-27. OPTIMIZING CLINICAL TRIAL DESIGN: PHARMACOKINETICS OF MARIZOMIB AND PANOBINOSTAT IN A NON-HUMAN PRIMATE MODEL. Neuro-Oncology. 21(Supplement_2). ii74–ii74. 2 indexed citations

2.

Figg, W D, et al.. (2009). Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. Clinical Pharmacology & Therapeutics. 85(2). 124–125. 9 indexed citations

3.

Figg, W D, William Dahut, Paul H. Duray, et al.. (2001). A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.. PubMed. 7(7). 1888–93. 243 indexed citations

4.

Figg, W D, et al.. (1999). Malignant ascites as only manifestation of metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 2(5-6). 290–293. 8 indexed citations

5.

Bergan, Raymond C., E Reed, Catherine E. Myers, et al.. (1999). A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.. PubMed. 5(9). 2366–73. 78 indexed citations

6.

Lush, Richard M., David Venzon, Paul H. Duray, et al.. (1998). Elevated Carcinoembryonic Antigen in Patients with Androgen-Independent Prostate Cancer. Journal of Investigative Medicine. 46(2). 66–72. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact